Biotech and Pharma Investor Stock Q&A with Roche (SIX: RO, ROG; OTCQX: RHHBY) and Sunshine Biopharma (OTCBB: SBFM) Discussing Lead Cancer Products

More Information

New York, New York – July 16, 2012 – ( Investorideas.com Newswire ) Investorideas.com, an investorresearch portal specializing in sector research including biotech and pharma stocks, issues a Q&Asnapshot of two biotech companies taking aim at aggressive forms of cancer; Roche (SIX: RO, ROG;OTCQX: RHHBY) with its Herceptin® cancer drug and Sunshine Biopharma Inc. (OTCBB: SBFM) with itslead compound, Adva-27a.The interview(s) gives investors insight into how a small biotech company, Sunshine Biopharma, plans totarget the cancer drug market of the future with its technology and collaborations and the historical pathof the largest biotech company in the world bringing Herceptin® to market, reaching sales of over $5billion in 2010.Roche (SIX: RO, ROG; OTCQX: RHHBY) /Genetech’s Herceptin:Q: Investorideas.com staff:When was the licensing agreement put in place with Genentech and Roche for Herceptin®?A: Nina Goworek, Investor Relations Officer for RocheGenentech and Roche signed a licensing agreement giving Roche exclusive marketing rights forHerceptin outside of the US in July 1998Q: Investorideas.com staff:What other cancers are targeted with Herceptin® other than HER2-positive breast cancer and what FDAapprovals are in place?A: Nina Goworek, Investor Relations Officer for RocheIn the US:September 1998 - Herceptin is approved for 1st-line Her2 positive metastatic breast cancer incombination with chemotherapy (paclitaxel) and also approved as a medicine to be used alone forwomen who had received prior chemotherapy (second- and third-line treatment),November 2006 - Herceptin is approved for adjuvant or early stage HER2 positive breast cancer whengiven with chemotherapy (doxorubicin, cyclophosphamide and paclitaxel), a combination called AC-THJanuary 2008 - approved as a stand-alone medicine following anthracycline-based chemotherapyMay 2008 - Herceptin and chemotherapy (docetaxel and carboplatin), known as TCH, was approved;Another AC-TH combination, comprised of Herceptin, doxorubicin, cyclophosphamide and docetaxel, wasalso approvedOctober 2010 - Herceptin is approved in combination with cisplatin and capecitabine or 5-fluorouracil,for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junctionadenocarcinoma, who have not received prior treatment for metastatic disease (1st-line)Q: Investorideas.com staff:The Company recently announced in June the FDA approved for Perjeta in combination with Herceptin-how does this combination improve results?A; Nina Goworek, Investor Relations Officer for RocheThe addition of Perjeta in combination with Herceptin plus docetaxel (chemo) showed an increase ofprogression free survival (PFS) from a median of 12.4 months to 18.5 months - an increase of 6.1months.Statistically significant overall survival top-line results were announced with the data to be presented at anupcoming medical meeting.Q: Investorideas.com staff:What is the current number of women with HER2-positive breast cancer have been treated withHerceptin?A; Nina Goworek, Investor Relations Officer for RocheAs of January 2012, there were roughly 440,000 patients treated with Herceptin in the US for allindications and more that 1.2 million people have been treated with Herceptin globally.Sunshine Biopharma Inc. (OTCBB: SBFM) and Adva-27aQ: Investorideas.comCan you give us a brief history of the development of Adva-27a?A: Mr. Camille Sebaaly, CFO of Sunshine Biopharma IncAdva-27a is a small molecule which we designed and synthesized de novo. The patents coveringAdva-27a and derivatives in the United States and Europe have issued recently. Various patents inother places around the world are still pending. Adva-27a was designed to specifically target multidrugresistant (or aggressive) types of cancer.Q: Investorideas.com staffFrom your recent press releases you now have data on both lung and breast cancer results for Adva-27a,potentially doubling the market potential. Can you give investors a brief summary of the results to date?A: Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc.There are different types of transporter proteins which when overexpressed make cancer cells resistant todrugs. Different multidrug resistant cancer types may overexpress different transporter proteins. Our datato date have shown that Adva-27a can overcome two multidrug resistance proteins: MDR1 and MRP1 aspresent in the breast cancer cells and the lung cancer cells we tested. Lung and breast cancer are thetwo most frequently encountered cancers in humans.Q: Investorideas.com staffHow do your collaborations with the State University of New York at Binghamton and McGill University’sJewish General Hospital in Montreal (Canada) help you take Adva-27a to clinical trials?A: Mr. Camille Sebaaly, CFO of Sunshine Biopharma IncWe are delighted for the help, dedication and contribution of these two of the finest institutions in theworld. They have and continue to be of great help to us in our efforts to put Adva-27a through the drugdevelopment stages. We anticipate that our first clinical trial will be done at the Jewish General Hospitalon breast cancer volunteers.Q: Investorideas.com staffFor investors looking at a small biotech company like yours, taking on the big pharma companies, how doyou address the massive financial and corporate undertaking of bringing Adva-27a to market?A: Mr. Camille Sebaaly, CFO of Sunshine Biopharma IncIt is indeed very costly to bring a drug to market. We have been fortunate in our financing efforts to dateand we hope to be able to continue to access the private and public markets for funding on an as neededbasis to continue the development of our flagship Adva-27a and bring it to market for cancer sufferersaround the world.Q: Investorideas.com staffDo you have any third party projections for the market potential of Adva-27a?A: Mr. Camille Sebaaly, CFO of Sunshine Biopharma IncWe have not commissioned any one to do projections of market potential of our Adva-27a. However, wedo know that important cancer drugs generally reach annual sales of about $1 billion within 1 to 2 years ofFDA approval. We believe Adva-27a will have a similar sales profile.About Sunshine Biopharma Inc. (OTCBB: SBFM):Sunshine Biopharma is a pharmaceutical company focused on the research, development andcommercialization of drugs for the treatment of various forms of cancer. The Company’s lead compound,Adva-27a targets aggressive forms of cancer.www.sunshinebiopharma.comAbout Roche (SIX: RO, ROG; OTCQX: RHHBY):Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combinedstrengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with trulydifferentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is alsothe world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetesmanagement. Roche's personalized healthcare strategy aims at providing medicines and diagnostictools that enable tangible improvements in the health, quality of life and survival of patients. In 2011,Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Groupposted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of theRoche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan.www.roche.comAbout InvestorIdeas.com:InvestorIdeas.com is a leader in investor stock research by sector, including biotech andpharma stocks. Other sectors include renewable energy, oil and gas, mining and tech stocks.Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.comFollow Investorideas.com on Twitter http://twitter.com/#!/InvestorideasFollow Investorideas.com on Facebook http://www.facebook.com/InvestorideasSign up for the free investor news and biotech stock alertsDisclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not makerecommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sitesshould be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featuredcompanies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.comfor news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 thBC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheetlisted companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894800-665-0411 - Source – www.Investorideas.com